117132-44-2

Basic information

• Product Name: 1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE
• Synonyms: TIMTEC-BB SBB011753;1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE;AKOS BC-2676;ASINEX-REAG BAS 12543298;ASISCHEM C56782;1-[2-(4-Methoxyphenoxy)ethyl]piperazine 2HCl;1-[2-(4-methoxyphenoxy)ethyl]piperazine hydrochloride;Piperazine, 1-[2-(4-methoxyphenoxy)ethyl]-
• CAS NO: 117132-44-2
• Molecular Formula: C₁₃H₂₀N₂O₂
• Molecular Weight: 236.31
• Mol File: 117132-44-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE(117132-44-2)
• EPA Substance Registry System: 1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE(117132-44-2)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 117132-44-2(Hazardous Substances Data)

Usage

General Description

1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE is a chemical compound with the molecular formula C13H20N2O2. It is a piperazine derivative with a phenyl and an ether group attached to the piperazine ring. 1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE is commonly used in the synthesis of pharmaceutical drugs and biologically active compounds. Its chemical structure makes it a potential candidate for the development of new medications for various medical conditions. Studies have shown that it exhibits potential pharmacological activities, and it is being researched for its therapeutic applications. Overall, 1-[2-(4-METHOXY-PHENOXY)-ETHYL]-PIPERAZINE is an important chemical compound with potential pharmaceutical and therapeutic applications.

Upstream product

• 22921-76-2 1-(2-bromoethoxy)-4-methoxybenzene 
• 110-85-0 piperazine 
• 150-76-5 4-methoxy-phenol 

Downstream Products

• 1132095-06-7 2-((4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methyl)-9H-xanthen-9-one 
• 1352792-18-7 thiophen-2-yl(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone 
• 1061182-95-3 N-(thiazol-2-yl)-2-(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)acetamide 
• 1386162-69-1 (1H-indol-2-yl)(4-(2-(4-methoxyphenoxy)ethyl)piperazin-1-yl)methanone 

Relevant articles and documents

Discovery, Optimization, and Characterization of ML417: A Novel and Highly Selective D3 Dopamine Receptor Agonist

To identify novel D3 dopamine receptor (D3R) agonists, we conducted a high-throughput screen using a β-arrestin recruitment assay. Counterscreening of the hit compounds provided an assessment of their selectivity, efficacy, and potency. The most promising scaffold was optimized through medicinal chemistry resulting in enhanced potency and selectivity. The optimized compound, ML417 (20), potently promotes D3R-mediated β-arrestin translocation, G protein activation, and ERK1/2 phosphorylation (pERK) while lacking activity at other dopamine receptors. Screening of ML417 against multiple G protein-coupled receptors revealed exceptional global selectivity. Molecular modeling suggests that ML417 interacts with the D3R in a unique manner, possibly explaining its remarkable selectivity. ML417 was also found to protect against neurodegeneration of dopaminergic neurons derived from iPSCs. Together with promising pharmacokinetics and toxicology profiles, these results suggest that ML417 is a novel and uniquely selective D3R agonist that may serve as both a research tool and a therapeutic lead for the treatment of neuropsychiatric disorders.

Discovery of 1-aryloxyethyl piperazine derivatives as Kv1.5 potassium channel inhibitors (part I)

Kv1.5 potassium channel is an efficacious and safe therapeutic target for the treatment of atrial fibrillation (AF), the most common arrhythmia that threatens human. Herein, by modifying the hit compound 7k from an in-house database, 48 derivatives were synthesized for the assay of their Kv1.5 inhibitory effects by whole cell patch clamp technique. Six compounds which showed better potency than the positive compound dronedarone were selected for the next evaluation of their drug-like properties. Compound 8 exhibited balanced solubility and permeability. It also showed acceptable pharmacodynamics profile with very low acute toxicity. Taking all these data into account, compound 8 can serve as a promising lead for the development of novel therapeutic agent for the treatment of AF.